VaiosKaranikas RocheSwitzerland

VaiosKaranikas
Vaios Karanikas, PhD, has more than 30 years of experience in the exploration, design and implementation of cancer immunotherapeutic candidates. In September 2011, he joined Roche at the RICZ as a Biomarker Experimental Medicine Leader leading cutting edge programs in early clinical development. He completed his training in Immunology at Monash University, Melbourne Australia and postdoctoral fellowships at the Austin Research Institute (Melbourne) and Ludwig Institute for Cancer research (Brussels). Dr. Karanikas has received numerous awards, competitive international funding and authored several papers in the field of cancer immunotherapy.

Wednesday 10 June 2026

Time Session
13:30
14:15
F.Hoffmann - La Roche Industry Symposium: Optimizing T-Cell Redirection: The Added Value of Costimulatory Bispecifics
Roche is pioneering costimulatory bispecifics targeting 4-1BB and CD28 to maximize the efficacy of T-cell bispecifics (TCBs) and enable chemotherapy-free regimens in early-line therapy. This session explores phase 1 biomarker data from FAP-4-1BBL, CD19-4-1BBL, and CD19-CD28 trials across solid and hematologic indications. We will present evidence of a costimulatory "Signal 2" mode of action and its contribution to clinical efficacy. Furthermore, we share findings on the distinct “personalities” of each costimulator, providing a roadmap for this emerging therapeutic class.
VaiosKaranikas Industry Moderator/ Chair RocheSwitzerland
KooroshKorfi Industry Speaker RocheSwitzerland
TamaraTanos Industry Speaker RocheSwitzerland
Room F6+7+8